Johnson Pharmacare (532154) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended December 31, 2024.

• Statutory auditors conducted a limited review and found no material misstatements.

Financial highlights

• Revenue from operations for the quarter ended December 31, 2024: Rs 0.45 lakhs, unchanged year-over-year.

• Net loss for the quarter: Rs 2.99 lakhs, compared to Rs 0.46 lakhs loss in the same quarter last year.

• Net loss for nine months ended December 31, 2024: Rs 7.06 lakhs, compared to Rs 19.42 lakhs loss in the prior year period.

• Total expenses for the quarter: Rs 2.99 lakhs, up from Rs 0.46 lakhs in the same quarter last year.

• Basic and diluted EPS for the quarter: Rs (0.00), unchanged year-over-year.

Key financial ratios and metrics

• Paid-up equity share capital as of December 31, 2024: Rs 5,500.00 lakhs.

• Other equity as of December 31, 2024: Rs 175.30 lakhs.